GO:0002846 regulation of T cell tolerance induction to tumor cell: Immune Tolerance Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002846 describes any process that modulates the frequency, rate, or extent of T cell tolerance induction to tumor cell, a biological process critical for tumor immune escape.
• T cell tolerance to tumors is driven by co-inhibitory receptors such as PD-1 and its ligands PD-L1/PD-L2, which suppress T cell activation and effector function.
• The tumor microenvironment actively promotes tolerance through PD-L1/PD-1 signaling, regulatory T cells, and metabolic factors like tryptophan depletion.
• Transcription factors NR4A1 and the co-inhibitory gene module (including PD-1, TIM-3, LAG-3) are key regulators of T cell dysfunction and tolerance induction.
• Calcineurin inhibitors can inhibit tolerance induction by suppressing terminal exhaustion of donor T cells after allogeneic hematopoietic cell transplantation.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of genes regulating T cell tolerance to tumors.
Description
Regulation of T cell tolerance induction to tumor cell (GO:0002846) is a biological process that encompasses any mechanism modulating the frequency, rate, or extent by which T cells become tolerant to tumor cells. This process is central to cancer immunology because it determines whether the immune system mounts an effective antitumor response or instead permits tumor progression through immune evasion. T cell tolerance to tumors can be induced by co-inhibitory pathways, regulatory T cells, and metabolic reprogramming within the tumor microenvironment. Understanding this regulation is essential for developing immunotherapies that break tolerance and restore antitumor immunity. The PD-1/PD-L1 axis is a well-established regulator of T cell tolerance, as PD-1 engagement delivers inhibitory signals that limit T cell activation and proliferation. Moreover, the tumor microenvironment exploits this axis to suppress T cell function, contributing to immune escape. Recent studies have identified transcriptional and metabolic regulators, such as NR4A1 and the AHR pathway, that further modulate tolerance induction. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0002846, its mechanisms, key genes, and experimental approaches.
regulation of T cell tolerance induction to tumor cell At A Glance
| GO ID | GO:0002846 |
|---|---|
| GO term | regulation of T cell tolerance induction to tumor cell |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the induction of T cell tolerance to tumor cells, affecting antitumor immune responses. |
| Related processes | T cell tolerance induction, immune evasion, tumor microenvironment immunosuppression. |
| Key regulators | PD-1, PD-L1, NR4A1, AHR, calcineurin, co-inhibitory receptors. |
| Disease relevance | Cancer immunotherapy resistance, autoimmune disease, transplant tolerance. |
What Is GO:0002846?
According to the Gene Ontology, GO:0002846 (regulation of T cell tolerance induction to tumor cell) is defined as any process that modulates the frequency, rate, or extent of T cell tolerance induction to tumor cell. In other words, it covers all molecular and cellular events that control how T cells become unresponsive or tolerant to tumor antigens, thereby influencing antitumor immunity.
Why Is regulation of T cell tolerance induction to tumor cell Important in Cell Biology?
GO:0002846 is critically important because it governs the balance between effective antitumor immunity and tumor immune escape. Dysregulation of this process leads to T cell exhaustion and tolerance, which are major barriers to successful cancer immunotherapy. Understanding the regulators of T cell tolerance induction can inform the development of novel therapeutic strategies, such as checkpoint inhibitors, to reinvigorate antitumor T cell responses.
• Determines the efficacy of immune checkpoint blockade therapies targeting PD-1/PD-L1.
• Contributes to tumor immune evasion and resistance to immunotherapy.
• Involves transcriptional regulators like NR4A1 that mediate T cell dysfunction.
• Modulated by metabolic factors such as tryptophan depletion and AHR signaling.
• Affected by calcineurin inhibitors in the context of allogeneic transplantation.
• Relevant to autoimmune diseases where tolerance breakdown leads to tissue damage.
• Potential target for enhancing CAR-T cell therapies by preventing tolerance induction.
• Key to understanding sex differences in immune responses and cancer outcomes.
• Provides biomarkers for predicting response to immunotherapies.
• Enables development of combination therapies to overcome tolerance.
What Happens During regulation of T cell tolerance induction to tumor cell?
Co-inhibitory receptor signaling
In simple terms: T cells have brakes called co-inhibitory receptors that, when engaged, stop them from attacking tumors.
Co-inhibitory receptors such as PD-1, TIM-3, and LAG-3 play a central role in regulating T cell tolerance induction to tumors. PD-1 engagement by its ligands PD-L1 and PD-L2 delivers inhibitory signals that attenuate T cell receptor signaling and promote tolerance. The tumor microenvironment often upregulates PD-L1 to suppress antitumor T cell responses, leading to immune escape. The co-inhibitory gene module, including PD-1, TIM-3, and LAG-3, is transcriptionally regulated by factors such as NR4A1, which mediates T cell dysfunction.
Transcriptional regulation of tolerance
In simple terms: Certain transcription factors act as master switches that turn on tolerance programs in T cells.
NR4A1 is a key transcription factor that promotes T cell dysfunction and tolerance induction. Genome-wide analysis identified NR4A1 as a mediator of T cell exhaustion, and its deletion enhances antitumor immunity. Additionally, the co-inhibitory gene module in T cells is induced and transcriptionally regulated by a network of transcription factors, including NFAT, which can be modulated by calcineurin inhibitors.
Metabolic and environmental factors
In simple terms: The tumor environment can starve T cells of nutrients or expose them to suppressive molecules, pushing them toward tolerance.
Tryptophan depletion in the tumor microenvironment sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, which potentiates the induction of regulatory T lymphocytes and promotes tolerance. This metabolic reprogramming favors T cell tolerance over activation. Additionally, macrophage efferocytosis induced by PI3Kγ inhibition and radiotherapy can promote tumor control by altering the immune microenvironment.
Role of calcineurin and terminal exhaustion
In simple terms: Calcineurin inhibitors, often used as immunosuppressants, can block the development of terminally exhausted T cells that contribute to tolerance.
Calcineurin inhibitor treatment inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allogeneic hematopoietic cell transplantation. This suggests that calcineurin signaling is involved in the regulation of T cell tolerance induction to tumors. The study highlights that terminal exhaustion is a key step in tolerance, and its suppression can enhance antitumor immunity.
Tumor microenvironment crosstalk
In simple terms: Tumors and immune cells talk to each other, and tumors often send signals that make T cells tolerant.
The tumor microenvironment plays a pivotal role in PD-L1/PD-1-mediated tumor immune escape, where tumor cells and immunosuppressive cells (e.g., regulatory T cells, macrophages) collaborate to induce T cell tolerance. Efferocytosis of dying tumor cells by macrophages can also influence the immune response, as shown in pancreatic cancer models where PI3Kγ inhibition and radiotherapy promoted tumor control. These interactions highlight the complex regulation of T cell tolerance induction in the tumor context.
Key Genes Involved in GO:0002846 regulation of T cell tolerance induction to tumor cell
The following genes and proteins are key players in the regulation of T cell tolerance induction to tumor cells, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDCD1 (PD-1) | Co-inhibitory receptor that suppresses T cell activation upon ligand binding | Target for immune checkpoint blockade; regulates tolerance induction |
| CD274 (PD-L1) | Ligand for PD-1; expressed on tumor cells and immune cells | Mediates tumor immune escape; biomarker for immunotherapy response |
| PDCD1LG2 (PD-L2) | Ligand for PD-1; alternative binding partner | Modulates T cell tolerance in tumors |
| NR4A1 | Transcription factor mediating T cell dysfunction and exhaustion | Key regulator of tolerance; potential therapeutic target |
| AHR | Aryl hydrocarbon receptor; senses kynurenine and promotes Treg induction | Metabolic regulator of tolerance; target for cancer immunotherapy |
| GCN2 | Kinase activated by amino acid deprivation; modulates translation | Links tryptophan depletion to tolerance induction |
| LAT1 (SLC7A5) | Amino acid transporter; mediates kynurenine uptake | Facilitates AHR activation and tolerance |
| NFATC1 | Transcription factor downstream of calcineurin; regulates T cell activation | Modulated by calcineurin inhibitors; affects tolerance |
| FOXP3 | Master transcription factor for regulatory T cells | Promotes tolerance; target for depletion strategies |
| TIM-3 (HAVCR2) | Co-inhibitory receptor; part of co-inhibitory module | Regulates T cell exhaustion and tolerance |
| LAG-3 | Co-inhibitory receptor; binds MHC class II | Part of co-inhibitory gene module; regulates tolerance |
| TIGIT | Co-inhibitory receptor; competes with CD226 | Modulates T cell responses in tumors |
| CTLA-4 | Co-inhibitory receptor; competes with CD28 | Regulates early T cell tolerance; target for ipilimumab |
| PI3Kγ (PIK3CG) | Kinase involved in macrophage polarization and efferocytosis | Inhibition promotes tumor control via efferocytosis |
| ADCY7 | Adenylyl cyclase; nuclear translocation potentiates antitumor immunity | Regulates T cell-mediated antitumor immunity in HCC |
| IL-2 | Cytokine that promotes T cell effector function | Counteracts tolerance; used in immunotherapy |
| TGF-β | Cytokine that promotes Treg differentiation and tolerance | Immunosuppressive factor in tumor microenvironment |
| IDO1 | Enzyme that catabolizes tryptophan to kynurenine | Depletes tryptophan and promotes tolerance |
How Is regulation of T cell tolerance induction to tumor cell Regulated?
The regulation of T cell tolerance induction to tumor cells is controlled by multiple signaling pathways and transcription factors. The PD-1/PD-L1 axis is a major regulatory pathway, where PD-1 engagement recruits phosphatases that dampen T cell receptor signaling. The co-inhibitory gene module, including PD-1, TIM-3, and LAG-3, is transcriptionally regulated by NFAT and NR4A1, which are activated upon T cell receptor stimulation. Calcineurin inhibitors, such as cyclosporine and tacrolimus, suppress NFAT activation and can inhibit tolerance induction by preventing terminal exhaustion of donor T cells after allo-HCT. Metabolic regulation also plays a role: tryptophan depletion activates GCN2 and increases AHR expression, which promotes regulatory T cell induction and tolerance. Additionally, PI3Kγ inhibition in macrophages enhances efferocytosis and can shift the immune response toward tumor control. These regulatory mechanisms are potential targets for therapeutic intervention to break tolerance and enhance antitumor immunity.
regulation of T cell tolerance induction to tumor cell and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDCD1 | Cancer immunotherapy resistance | PD-1 knockout mice or cell lines; syngeneic tumor models |
| CD274 | Tumor immune escape | PD-L1 overexpression in tumor cells; co-culture with T cells |
| NR4A1 | T cell exhaustion and dysfunction | NR4A1 knockout mice; tumor challenge models |
| AHR | Tolerance induction in cancer | AHR knockout mice; tryptophan depletion models |
| PIK3CG | Pancreatic cancer immune evasion | PI3Kγ inhibitor treatment in mouse models |
Cancer immunotherapy resistance
T cell tolerance induction to tumors is a major mechanism of resistance to immune checkpoint inhibitors. Upregulation of PD-L1 in the tumor microenvironment leads to PD-1-mediated T cell suppression and immune escape. Tumors with high NR4A1 expression exhibit T cell dysfunction and poor response to immunotherapy. Targeting regulators of tolerance, such as NR4A1 or AHR, could overcome resistance.
Autoimmune diseases
While tolerance to tumors is detrimental, breakdown of tolerance to self-antigens causes autoimmune diseases. Understanding GO:0002846 may provide insights into how tolerance is regulated in different contexts. For example, calcineurin inhibitors are used to treat autoimmune diseases by suppressing T cell activation, but their effect on tolerance induction is complex.
Transplant tolerance
In allogeneic hematopoietic cell transplantation, calcineurin inhibitors inhibit tolerance induction by suppressing terminal exhaustion of donor T cells, which can affect graft-versus-tumor effects. This highlights the dual role of tolerance regulation in transplantation and cancer.
Metabolic disorders and cancer
Tryptophan metabolism and AHR signaling link metabolic changes in the tumor microenvironment to T cell tolerance. Tryptophan depletion sensitizes the AHR pathway, promoting regulatory T cell induction and tolerance, which can contribute to cancer progression. Targeting this pathway may improve antitumor immunity.
From regulation of T cell tolerance induction to tumor cell-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PD-1 regulate T cell tolerance to tumors? | PD-1 knockout mice or CRISPR KO in T cells |
| What is the role of NR4A1 in T cell dysfunction? | NR4A1 knockout or overexpression in T cells |
| How does AHR signaling affect tolerance? | AHR point mutation or knockout in T cells |
| Can calcineurin inhibition modulate tolerance? | Calcineurin inhibitor treatment in allo-HCT models |
| Does PI3Kγ inhibition enhance efferocytosis? | PI3Kγ knockout macrophages or inhibitors |
| What is the impact of ADCY7 nuclear translocation? | ADCY7 knock-in or knockout in HCC models |
How to Study the regulation of T cell tolerance induction to tumor cell Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene essentiality for tolerance induction | Identify novel regulators in T cells |
| RNA-seq | Transcriptional profiles | Compare tolerant vs effector T cells |
| ATAC-seq | Chromatin accessibility | Identify regulatory elements in tolerance genes |
| Flow cytometry | Surface markers and cytokine production | Assess T cell exhaustion and tolerance |
| Metabolomics | Tryptophan and kynurenine levels | Study metabolic regulation of tolerance |
| Phospho-proteomics | Signaling pathways | Map PD-1 downstream signaling |
| Adoptive transfer | In vivo T cell function | Test gene knockout effects on tumor growth |
| Immunohistochemistry | T cell infiltration and PD-L1 expression | Correlate with clinical outcomes |
CRISPR screening for tolerance regulators
Genome-wide CRISPR knockout screens can identify genes that regulate T cell tolerance induction to tumors. For example, a screen in T cells co-cultured with tumor cells can reveal negative regulators of T cell activation, such as PD-1 or NR4A1. This approach enables unbiased discovery of novel targets.
Transcriptomic profiling of tolerant T cells
RNA-seq of T cells from tumor-bearing mice or patients can reveal transcriptional signatures of tolerance, including upregulation of co-inhibitory receptors and exhaustion markers. Comparing tolerant versus effector T cells identifies key regulators.
Functional validation with knockout models
CRISPR knockout of candidate genes in T cells followed by adoptive transfer into tumor-bearing mice can validate their role in tolerance induction. For instance, NR4A1 knockout enhances antitumor immunity.
Metabolic and signaling assays
Assays measuring tryptophan depletion, kynurenine levels, and AHR activation can elucidate metabolic regulation of tolerance. Phospho-flow cytometry can assess signaling downstream of PD-1.
How CRISPR Can Be Used to Study GO:0002846 regulation of T cell tolerance induction to tumor cell
Knockout
CRISPR knockout of genes such as PDCD1, NR4A1, or AHR in T cells or tumor cells can determine their causal role in regulating T cell tolerance induction to tumors. For example, PD-1 knockout T cells exhibit enhanced antitumor activity. NR4A1 knockout reduces T cell exhaustion and improves tumor control.
Point Mutation
Introducing point mutations in genes like PDCD1 or AHR can dissect specific signaling domains or DNA-binding sites required for tolerance induction. For instance, mutation of the PD-1 immunoreceptor tyrosine-based inhibitory motif (ITIM) can abolish its inhibitory function.
Knock-in
Knock-in of reporter genes (e.g., GFP) or epitope tags into endogenous loci such as PDCD1 or NR4A1 allows tracking of expression and localization during tolerance induction. This can reveal when and where these genes are activated in the tumor microenvironment.
Overexpression
Overexpression of tolerance-promoting genes like PD-L1 or AHR in tumor cells or T cells can model immune evasion and test therapeutic interventions. For example, PD-L1 overexpression in tumor cells suppresses T cell responses, mimicking the tumor microenvironment.
How EDITGENE Supports regulation of T cell tolerance induction to tumor cell Research
Researchers studying regulation of T cell tolerance induction to tumor cell-related genes often need to determine whether a candidate gene is causally involved in tolerance or merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal studies, from gene knockout to precise point mutations and knock-ins, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for regulation of T cell tolerance induction to tumor cell research.
Frequently Asked Questions About regulation of T cell tolerance induction to tumor cell
What is GO:0002846?
GO:0002846 is the Gene Ontology term for regulation of T cell tolerance induction to tumor cell, a biological process that modulates how T cells become tolerant to tumors.
What genes are involved in regulation of T cell tolerance induction to tumor cell?
Key genes include PDCD1 (PD-1), CD274 (PD-L1), NR4A1, AHR, and others involved in co-inhibition and metabolic regulation.
How does PD-1 regulate T cell tolerance to tumors?
PD-1 engagement by PD-L1/PD-L2 delivers inhibitory signals that suppress T cell activation and promote tolerance, allowing tumor immune escape.
What is the role of NR4A1 in T cell tolerance?
NR4A1 is a transcription factor that mediates T cell dysfunction and exhaustion, and its knockout enhances antitumor immunity.
How does tryptophan depletion affect T cell tolerance?
Tryptophan depletion activates GCN2 and increases AHR expression, promoting regulatory T cell induction and tolerance.
Can calcineurin inhibitors affect T cell tolerance induction?
Yes, calcineurin inhibitors inhibit tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.
What experimental models are used to study GO:0002846?
Common models include CRISPR knockout mice or cell lines, adoptive transfer models, and syngeneic tumor models.
How can CRISPR screening identify regulators of T cell tolerance?
Genome-wide CRISPR knockout screens in T cells co-cultured with tumor cells can identify genes whose loss enhances T cell activation and reduces tolerance.
What is the tumor microenvironment's role in T cell tolerance?
The tumor microenvironment upregulates PD-L1 and other suppressive factors that induce T cell tolerance and immune escape.
Why is regulation of T cell tolerance induction important for cancer immunotherapy?
Understanding this process helps develop strategies to overcome immunotherapy resistance and improve antitumor responses.
Conclusion
Regulation of T cell tolerance induction to tumor cell (GO:0002846) is a pivotal biological process in cancer immunology, governing whether T cells mount effective antitumor responses or become tolerant. Key regulators include co-inhibitory receptors like PD-1, transcription factors such as NR4A1, and metabolic pathways involving AHR and tryptophan depletion. Targeting these regulators holds promise for overcoming immune evasion and enhancing immunotherapy efficacy. Continued research using CRISPR-based models and advanced screening will further elucidate the mechanisms and identify new therapeutic targets.
References
- 1. Keir ME et al.. 2008. PD-1 and its ligands in tolerance and immunity.. Annu Rev Immunol 26:677-704 PMID: 18173375
- 2. Jiang X et al.. 2019. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.. Mol Cancer 18(1):10 PMID: 30646912
- 3. Russell SN et al.. 2025. Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control.. Gut 74(5):825-839 PMID: 39788719
- 4. Chihara N et al.. 2018. Induction and transcriptional regulation of the co-inhibitory gene module in T cells.. Nature 558(7710):454-459 PMID: 29899446
- 5. Liu X et al.. 2019. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction.. Nature 567(7749):525-529 PMID: 30814730
- 6. Chen J et al.. 2024. Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC.. Gut 74(1):128-140 PMID: 39349007
- 7. Senjo H et al.. 2023. Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.. Blood 142(5):477-492 PMID: 37216687
- 8. Solvay M et al.. 2023. Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.. J Immunother Cancer 11(6) PMID: 37344101
